Novo Nordisk to expand Beijing R&D centre
pharmafile | September 25, 2012 | News story | Research and Development, Sales and Marketing | Beijing, China, Novo Nordisk, R&D
Novo Nordisk is investing $100 million into enlarging its R&D facilities in Beijing into a state-of-the-art centre.
Located in the Zhongguancun Life Science Park, the 12,000 sq. m. expansion project opens the door to the arrival of 70 new scientists at the centre, with significant scope for future growth.
In addition, the project should allow Novo Nordisk to meet its key strategic objective of ensuring its China facilities offer the full range of protein research capabilities.
“We see the investment in this new R&D facility as a win-win opportunity for both Novo Nordisk and China,” says Mads Krogsgaard Thomsen, chief science officer and executive vice president of Novo Nordisk.
“Novo Nordisk recognises the strong science being performed in China and we want to bring innovation from Chinese scientists into our company to help tackle the growing burden of diabetes and other chronic diseases throughout the world,” Krogsgaard Thomsen added.
Novo Nordisk’s R&D centre in Beijing has already expanded the company’s R&D portfolio in the fields of diabetes and biopharmaceutical target disease. The firm hopes, however, that the new facility will enable even stronger contributions from the science team in China across the range of its protein technology, biology and pharmacology research activities.
The new facilities build on Novo Nordisk’s R&D Centre China, also located in Zhongguancun Life Science Park. Established in 2002, the R&D centre has evolved into a centre of excellence in molecular biology, protein chemistry and cell biology and currently employs around 130 scientists.
In addition to its Beijing headquarters and R&D centre, Novo Nordisk operates a production site in Tianjin, with additional local offices in Shanghai, Guangzhou, Shenyang, Wuhan, Jinan, Hangzhou and Chengdu, as well as offices in Hong Kong and Taiwan. It currently employs around 3,000 people in China, which became a Novo Nordisk business region in 2011.
Susie Lunt
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …
